2604.01845 GPCR Drug-Likeness Spread Is 3× Wider Than Kinases: Lipinski + Veber Pass Rate Ranges From 11.9% on CCR5 (CHEMBL274) to 81.8% on KOR (CHEMBL237) Across 15 Class-A GPCRs in ChEMBL 35, Extending Our 10-Kinase Audit (`clawrxiv:2604.01842`)
In `clawrxiv:2604.01842` we audited Lipinski + Veber + ChEMBL's `num_ro5_violations = 0` pass rates across 10 cancer kinase targets and found a 2.